# Ensysce Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Ensysce Biosciences, Inc.). ## Overview Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing abuse-deterrent and safer opioid-based pain therapies. Its core work centers on PF614 and PF614-MPAR, drug candidates designed to improve pain control while reducing misuse, overdose, and other safety risks. ## Products & services • PF614 abuse-deterrent opioid candidate • PF614-MPAR combination pain therapy program • Drug development and formulation services • Clinical, manufacturing, packaging, and testing support - **Drug Candidates** (70%) — Proprietary therapeutic programs in development, centered on PF614 and PF614-MPAR. - **Development Services** (30%) — Research, formulation, and pre-commercial development work tied to its pipeline. - PF614 abuse-deterrent opioid candidate - PF614-MPAR combination pain therapy program - Drug development and formulation services - Clinical, manufacturing, packaging, and testing support ## Customers The company primarily serves pharmaceutical development partners, manufacturing collaborators, and future healthcare prescribers and patients if its candidates reach commercialization. In the near term, value is driven by research and development counterparties such as Galephar Pharmaceutical Research, which supports manufacturing and testing activities under project agreements. - **Pharmaceutical development partners** (primary) — Partners that fund, co-develop, or manufacture PF614 and PF614-MPAR programs. - **Clinical and regulatory ecosystem** (primary) — Clinical investigators, CROs, and regulators involved in advancing candidates through trials. - **Future pain-treatment prescribers** (secondary) — Physicians and healthcare systems that would prescribe the products if approved. - **Patients with chronic or acute pain** (secondary) — End users of the eventual approved therapies, especially where abuse deterrence matters. - Pharmaceutical development partners funding or supporting pipeline work - Manufacturing and testing collaborators for clinical-stage programs - Future prescribers seeking safer opioid pain options - Patients needing pain treatment with lower misuse risk ## Geography Ensysce is headquartered in the United States and its business is centered on U.S.-based development, financing, and regulatory activity. The recent Galephar agreement adds Puerto Rico manufacturing and development support, showing that operational execution can extend beyond the mainland U.S. as the pipeline advances. - Headquartered in the United States - Core development and corporate activity are U.S.-based - Puerto Rico partner supports manufacturing and testing - Geography matters because clinical and regulatory work is U.S.-centric ## Strategy The company’s strategy is to advance PF614 and PF614-MPAR through development while using external partners to support manufacturing and testing. The January 2025 agreement with Galephar indicates a capital-efficient approach that shifts part of development execution to a specialized partner while preserving ownership of the programs. - **Advance PF614 and PF614-MPAR development** (short-term) — Clinical and regulatory progress is the main value driver for a pre-commercial biotech. - **Outsource manufacturing and testing execution** (short-term) — Partnering can reduce fixed costs and speed technical development. - **Maintain financing flexibility** (medium-term) — Development-stage companies need capital to fund trials and operations before product revenue. - Advance PF614 and PF614-MPAR through development milestones - Use partner manufacturing to reduce internal capital needs - Structure collaborations to fund R&D and testing work - Preserve optionality for future commercialization or partnering ## Risks Ensysce faces the typical risks of a clinical-stage pharmaceutical company: trial failure, regulatory setbacks, and the possibility that its candidates never reach commercialization. Its dependence on external funding and partner execution adds dilution, counterparty, and development-timing risk, while opioid-focused programs also face heightened scrutiny around safety, abuse deterrence, and market acceptance. - **Pipeline development failure** [critical] — The company’s value depends heavily on PF614 and PF614-MPAR advancing successfully. - **Regulatory and clinical trial risk** [high] — Drug candidates can be delayed, rejected, or require additional studies. - **Financing and dilution risk** [high] — Development-stage biotech companies often rely on equity or equity-linked funding. - **Counterparty and execution risk** [medium] — Manufacturing and testing are partly outsourced, so partner performance affects timelines. - **Opioid market and reputational risk** [medium] — Opioid therapies face heightened safety, legal, and adoption barriers. - Clinical failure could eliminate value in PF614 and PF614-MPAR - Regulatory delays can push out timelines and increase cash burn - Dependence on external financing may cause dilution - Partner execution risk can affect manufacturing and testing milestones - Opioid safety scrutiny may limit adoption or approval ## Accounting As a development-stage biotech, the most important accounting issues are R&D expense recognition, equity-based consideration, and valuation of any milestone-linked obligations. The Galephar agreement includes restricted stock grants and milestone-based share or cash payments, which can create judgment around fair value, timing of expense recognition, and dilution effects in reported results. - **Research and development expense recognition** — Affects reported loss level and comparability across periods - **Equity-based consideration in the Galephar agreement** — Can increase noncash expense and dilute shareholders - **Contingent milestone obligations** — Can affect liabilities and period-to-period expense timing - R&D costs are likely expensed as incurred, affecting near-term losses - Restricted stock grants can create noncash compensation expense - Milestone-based share payments require fair value judgment - Partner agreements may create contingent liabilities or accruals - Development-stage results can be volatile quarter to quarter --- *Last updated: 2026-04-28T20:05:07.601618+00:00*